51 /100
HIGH RISK
Score updated Jul 14, 2026

FBIO — Fortress Biotech, Inc. Dilution Risk Tracker

Track FBIO dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track FBIO — Get alerts when the score changes →

As of July 14, 2026, Fortress Biotech, Inc. (FBIO) has a DilutionWatch DilutionScore of 51/100, rated HIGH dilution risk. Fortress Biotech, Inc. has a market capitalization of $93.01M, 82.47M shares outstanding, 22 institutional holders tracked. Key dilution vectors include approximately 999 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
0
📊 Float Risk
85
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
20%
🔁 Convertible Conversion 40%
• Significant convertible debt: 16% potential dilution
• Elevated convertible risk (60/100)
🔔 Track FBIO — Get forecast alerts →

💹 Market Data

Market Cap$93.01M
Shares Outstanding82.47M
Float22.38M
Cash$255.84M
Debt$398.0K
Short InterestN/A

🏛 Institutional Holdings

22 institutional holders · 534.2K shares
#1 Kestra Advisory Services, LLC 176.0K shares
#2 GEODE CAPITAL MANAGEMENT, LLC 92.8K shares
#3 BlackRock, Inc. 84.7K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest5.31M
Days to Cover8.5
% of Float23.7%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2020
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for FBIO Shareholders

Fortress Biotech, Inc. (FBIO) has a DilutionScore of 51/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch's EDGAR monitoring for FBIO shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for FBIO in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for FBIO alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track FBIO Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking FBIO — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for FBIO
📊 FBIO FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 FBIO Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.